Lingfang Biology
Latest round
- Series A
Last raised
- Nov 2021
Total raised
- Undisclosed
Investors
- 2
About Lingfang Biology
Established in 2020 and based in Shenzhen, China, Lingfang Biology is a pharmaceutical company that provides anti-tumor targeted drugs. The company's R&D team has decades of experience in new drug development. The company focuses on the research and development of anti-tumor targeted drugs for gastric cancer, liver cancer, pancreatic cancer, and etc. The company has six product lines and some of its products are in pre-clinical development stage.
Who invested in Lingfang Biology
2 investors across 1 round
See all investors in Lingfang Biology
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Nov 1, 2021
Amount
Undisclosed
Investors
Questions about Lingfang Biology
Who invested in Lingfang Biology?
Lingfang Biology has 2 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Lingfang Biology raised?
Lingfang Biology has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Lingfang Biology last raise money?
Lingfang Biology's most recent round on record is a Series A, in Nov 2021.
What does Lingfang Biology do?
Established in 2020 and based in Shenzhen, China, Lingfang Biology is a pharmaceutical company that provides anti-tumor targeted drugs.
Where is Lingfang Biology headquartered?
Lingfang Biology is headquartered in Shenzhen, China.
Which VCs invest in companies like Lingfang Biology?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back pharmaceuticals companies at Lingfang Biology's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series A
Raising like Lingfang Biology? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.